ClinicalTrials.gg
RecruitingNCT04053478Updated Apr 6, 2026

Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study

An interventional study of Ephedrine and Phenylephrine in Hypotension, sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital. Recruiting at 1 site in Canada. Open to female participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Samuel Lunenfeld Research Institute, Mount Sinai Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Non-randomized
Ages
19 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing ephedrine in Hypotension — 4 open to participants now, 4 under way, none of them phase 3. Ephedrine · Hypotension.

Planned enrollment
7th of 22
144 · median 120
Started
2019
with 2 others
No phase
6 of 22
2 open now
Registered
13th of 22
by date

Among the 22 studies testing ephedrine in Hypotension, this one is the 7th largest by planned enrollment, is one of 3 that started in 2019, is one of 6 with no phase, and was the 13th registered.

Hypotension

892 studies on the registry are indexed under Hypotension; 199 are open to participants now.

Browse Hypotension studies →

Open to participants now

4 of the 22 studies testing ephedrine in Hypotension are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ephedrine

Ephedrine: first FDA approval 2016 (AKOVAZ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Hypotension studies recruiting now, 53 (46%) set no upper age limit and 36 (32%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.

This study: 19 Years to 40 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ephedrine in Hypotension, or all of them as a file.
02

Study summary

Hypotension is one of the most common adverse effects of spinal anesthesia for cesarean deliveries, affecting as many as 55-90% of mothers. Hypotension during cesarean deliveries can have detrimental effects on the mother and neonate. Various vasopressors, such as ephedrine, phenylephrine and more recently norepinephrine, have been used for the prevention and treatment of hypotension at cesarean deliveries.

Ephedrine was historically considered as the gold standard vasopressor for the management of hypotension during cesarean deliveries. This was based on studies in animal models that showed preserved uteroplacental circulation with ephedrine and not with phenylephrine. However, multiple studies in the past several decades have shown that phenylephrine compared with ephedrine results in a more favorable fetal acid-base status. Consequently, the use of phenylephrine for blood pressure management during cesarean deliveries increased. Recently, norepinephrine was introduced in the obstetrical practice for the management of hypotension at cesarean deliveries, due to its ability to maintain maternal cardiac output better than phenylephrine.

Studies have also investigated the use of vasopressin to limit hypotension during CD. There have been case reports of successful vasopressin usage to treat post-spinal hypotension after CD in patients with advanced idiopathic pulmonary arterial hypertension as well as severe mitral stenosis with pulmonary hypertension. Its effect was associated with hemodynamic stability without evidence of harm to the mother or child. However, much controversy still exists surrounding the choice of vasopressor in the obstetric population, in large part due to their varying efficacies, and maternal and fetal effects.

Vasopressors used for the treatment of hypotension during cesarean deliveries can have significant direct or indirect effects on the perfusion of uteroplacental and umbilical vessels. Reduction of uteroplacental perfusion and constriction of umbilical vessels can result in fetal acidosis, however, the mechanisms for these effects are unclear. The investigators hypothesize that ephedrine, phenylephrine and norepinephrine and vasopressin have variable effects on the contractility of pregnant myometrium and umbilical arteries due to their variable actions on adrenergic alpha (α) and beta (β) receptors, as well as vasopressin1 and vasopressin2 receptors located in these tissues.

Read the detailed description

One of the major concerns addressed in the literature is the risk of fetal acidosis related to the use of vasopressors, which varies according to the type of drug used. Since severe fetal acidosis is associated with a two- and four-fold increase in neonatal morbidity and mortality, respectively, it is important to understand the mechanism by which these medications may contribute to fetal acidosis.

It is well known that reduced uteroplacental blood flow can result in impaired fetal oxygenation and fetal acidosis. This can occur indirectly via compression of vessels due to myometrial contractions or directly by vasoactive effects on umbilical vessels. So far, no studies have directly explored the role of the aforementioned vasopressors on myometrial contractions and umbilical vessel vasoconstriction. An in-vitro approach in isolated tissues will eliminate many clinical confounding variables, allowing direct comparison of the drugs in a controlled environment, and providing insight into the contractile mechanisms responsible for their neonatal effects.

There is currently no consensus as to which vasopressor is best for the management of hypotension in obstetric patients and the mitigation of fetal acidosis. A survey of the members of the Society of Obstetric Anesthesia and Perinatology suggested significant variation in the practice of vasopressor use during cesarean deliveries. The evidence from animal studies contradicts the effects seen in human studies. This is possibly related to species differences in adrenergic receptor distribution, affinity to vasopressors, or placental transfer of vasopressors. It is well known that reduced uteroplacental blood flow can result in impaired fetal oxygenation and fetal acidosis. This can occur indirectly via compression of vessels due to myometrial contractions or directly by vasoactive effects on umbilical arteries. However, none of the studies so far have directly explored the role of the aforementioned vasopressors on myometrial contractions and umbilical artery vasoconstriction. An in-vitro approach in isolated tissues will eliminate many clinical confounding variables, allowing direct comparison of the drugs in a controlled environment, and providing insight into the contractile mechanisms responsible for their neonatal effects.

03

Conditions studied

  • Hypotension

Keywords

  • vasopressor
  • ephedrine
  • phenylephrine
  • norepinephrine
  • umbilical arteries
  • uterine contraction
  • fetal acidosis
  • vasopressin
04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who give written consent to participate in this study
  • Patients with gestational age 37-41 weeks
  • Patients of 19-40 years
  • Non-laboring patients, not exposed to exogenous oxytocin
  • Patients requiring elective primary or first repeat caesarean delivery
  • Patients undergoing caesarean delivery under spinal anesthesia

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to give written
  • Patients who require general anesthesia
  • Patients in labor and those receiving oxytocin for induction of labor
  • Emergency caesarean delivery in labor
  • Patients who have had previous uterine surgery or >1 previous caesarean delivery
  • Patients with any condition predisposing to uterine atony
  • Patients on medications that could affect myometrial contractility, such as insulin, nifedipine, labetolol or magnesium sulfate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    Myometrium + Ephedrine

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

    Drug: Ephedrine

  • Experimental
    Myometrium + Phenylephrine

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

    Drug: Phenylephrine

  • Experimental
    Myometrium + Norepinephrine

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

    Drug: Norepinephrine

  • Experimental
    Myometrium + Vasopressin

    The myometrial samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

    Drug: Vasopressin

  • Experimental
    Umbilical artery + Ephedrine

    The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

    Drug: Ephedrine

  • Experimental
    Umbilical artery + Phenylephrine

    The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

    Drug: Phenylephrine

  • Experimental
    Umbilical artery + Norepinephrine

    The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

    Drug: Norepinephrine

  • Experimental
    Umbilical artery + Vasopressin

    The umbilical artery samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

    Drug: Vasopressin

  • Experimental
    Umbilical vein + Ephedrine

    The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of ephedrine

    Drug: Ephedrine

  • Experimental
    Umbilical vein + Phenylephrine

    The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of phenylephrine

    Drug: Phenylephrine

  • Experimental
    Umbilical vein + Norepinephrine

    The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of norepinephrine

    Drug: Norepinephrine

  • Experimental
    Umbilical vein + Vasopressin

    The umbilical vein samples are bathed in physiological salt solution (PSS) with increasing concentrations of vasopressin

    Drug: Vasopressin

Interventions

06

What researchers measure

Primary outcomes

  1. Motility index

    Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude). Frequency and amplitude are secondary outcome measures as described below. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.

    Time frame: 4 hours

Secondary outcomes

  1. Amplitude of contraction

    The maximum extent of uterine muscle and umbilical vessel contractions, measured in grams (g). The analysis is undertaken by attaching myometrial strips and umbilical vessel rings between an isometric force transducer and the base of an organ bath chamber.

    Time frame: 4 hours

  2. Frequency of contraction

    The number of contractions in uterine muscle (myometrium) and umbilical vessel rings over 10 minutes, spontaneously and in response to an agonist. The analysis is undertaken by attaching myometrial strips and umbilical vessel rings between an isometric force transducer and the base of an organ bath chamber.

    Time frame: 4 hours

  3. Integrated area under response curve (AUC)

    Time frame: 4 hours

07

Study locations

1 of 1 sites recruiting
  • Mount Sinai Hospital
    Toronto, Ontario M5G1X5, Canada
    Recruiting
    • Mrinalini Balki, MD · Contactmrinalini.balki@uhn.ca · 416-586-4800
    • Alice Luca, MSc · Sub investigator
    • Jose Carvalho, MD · Sub investigator
    • John Kingdom, MD · Sub investigator
    • Chinaza Egbuta, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Dec 2026, 89 months after the start.

Of 213 non-industry interventional studies with no phase under Hypotension, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 89 months is above that.

Counting every sponsor, half of 220 studies reached it within 12 months; a quarter within 6 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2019
First posted
Aug 12, 2019
StartActual
Jul 8, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04053478
Responsible party
Sponsor
First posted
Aug 12, 2019
Start date
Jul 8, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Mrinalini Balki, MD
Contact
mrinalini.balki@uhn.ca
416-586-4800 ext. 5270
Mrinalini Balki, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ephedrine · Phenylephrine · Norepinephrine · Arginine Vasopressin

Start the discussion